Displaying drugs 8876 - 8900 of 11996 in total
GW-274150
GW274150 has been used in trials studying the treatment and prevention of Asthma, Migraine, Migraine Disorders, and Arthritis, Rheumatoid.
Investigational
Matched Iupac: … (2S)-2-amino-4-[(2-ethanimidamidoethyl)sulfanyl]butanoic acid …
PCI-27483
PCI-27483 has been used in trials studying the treatment of Pancreatic Cancer, Ductal Adrenocarcinoma, and Exocrine Pancreatic Cancer.
Investigational
Matched Iupac: … (2S)-2-{2-[5-(6-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2',6-dihydroxy-5'-sulfamoyl-[1,1'-biphenyl]-3- …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
AC-262536
A selective androgen receptor modulator.
Experimental
Matched Iupac: … 4-[(1R,3R,5S)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]naphthalene-1-carbonitrile …
NP-G2-044
NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Investigational
Matched Iupac: … 2-methyl-N-(1-{[4-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)furan-3-carboxamide …
Matched Description: … NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis …
Matched Description: … NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis …
EU204
EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.
Investigational
Matched Description: … EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and …
NTLA-2002
NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9. It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.
Investigational
NTLA-2001
NTLA-2001 is a clustered regularly interspaced short palindromic repeats CRISPR/ Cas9-based gene therapy consisting of a single guide RNA targeting the human TTR gene and a messenger RNA encoding Cas9.
Investigational
Tyrphostin AG 555
Experimental
Matched Iupac: … (2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)prop-2-enamide …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Olokizumab
Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome....
Investigational
Matched Description: … Olokizumab is a humanized anti-IL-6 IgG4κ antibody that directly blocks gp130 binding at IL-6 Site 3. …
4-Oxosebacic Acid
Experimental
Matched Name: … 4-Oxosebacic Acid …
Matched Iupac: … 4-oxodecanedioic acid …
Matched Iupac: … 4-oxodecanedioic acid …
SAR445136
SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy. It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous HbF production in erythrocytes (RBC). It was formerly investigated for the...
Investigational
Ethanesulfonic acid
Experimental
Matched Synonyms: … 1-ethanesulfonic acid ... 2-ethanesulfonic acid …
AVR118
AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant...
Investigational
REV131
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
V1003
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
R1204
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
CYC116
CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.
Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which...
Investigational
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Actelion-1
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Matched Name: … Actelion-1 …
Matched Description: … Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
BNC105
Investigational
Matched Iupac: … {[6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)-1-benzofuran-7-yl]oxy}phosphonic acid …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
ALGRX 1207
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
Displaying drugs 8876 - 8900 of 11996 in total